UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2021

Neoleukin Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-36327 (Commission File Number) 98-0542593 (IRS Employer Identification No.)

188 East Blaine Street, Suite 450 Seattle, Washington 98102 (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (866) 245-0312

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Derecommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.000001 par value	NLTX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events

Neoleukin Therapeutics, Inc. (the "Company") has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOLEUKIN THERAPEUTICS, INC.

By:

By: /s/ Robert Ho Robert Ho Chief Financial Officer

Date: November 16, 2021



Corporate Presentation November 2021

Forward Looking Statements

Certain of the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates. properties of its product candidates, availability of data, the use and sufficiency of its cash resources and other statements containing the words "anticipate," "believe," "expect," "may," "plan," "project," "potential," "will," "would," "could," "continue," and similar expressions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties associated with regulatory review of clinical trials; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any product candidates and the potential safety, efficacy or clinical utility of or any product candidates; further impacts of COVID-19 on our operations; and other factors discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 as filed with the Securities and Exchange Commission. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by the Company is contained in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent reports, filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Leader in Therapeutic Protein Design First Program: Cancer Immunotherapy



Platform technology: computational protein design methods for creating de novo Neoleukin™ cytokine mimetics



NL-201 program: highly potent, nonalpha, combined IL-2 and IL-15 receptor agonist for cancer immunotherapy

Expanding opportunities: building expertise in de novo protein therapeutics for cancer and inflammation

neoleukin⁻



Neoleukin[™]Progress in 2021

- Moved into new headquarters in Seattle (~33,000 sq ft)
- Initiated Phase 1 clinical trial in solid tumors for NL-201
- Plan to initiate hematologic malignancy trial in 2022
- · Presented preclinical IL-2/IL-15 inhibitor molecule for inflammatory conditions
- Executive leadership: Priti Patel, CMO; Bill Arthur, VP, Head of Research
- Added expertise in CMC and Clinical (~100 FTE)
- · Continuing to build our pipeline and technology





Leadership Team



Jonathan Drachman, M.D. Chief Executive Officer Prior: CMO, EVP R&D, Seagen



Bill Arthur, Ph.D. VP & Head of Research Prior: Seagen, Merck & Co.





Robert Ho Chief Financial Officer Prior: Morgan Stanley & Co., DaVita



Holly Vance, J.D., Pharm.D. General Counsel Prior: Gates Foundation





Priti Patel, M.D., M.S. Chief Medical Officer Prior: AstraZeneca, Acerta Pharma



Carl Walkey, Ph.D. Senior VP, Corporate Development Prior: Postdoctoral Fellow, UW-IPD




Samantha Willing Senior VP, People Prior: Seagen, Microsoft


NL-201: *De Novo* IL-2/IL-15 Agonist Designed to retain benefits of IL-2 without drawbacks

100% non-alpha: no residual alpha subunit binding
 No bias toward T-regulatory or endothelial cells

- More potent than IL-2 and IL-15
- Activates CD8+ naïve T-cells and NK cells

Hydrophilic, compact, increased thermal stability








Source: Silva et al. Nature, 565, 186-191 (2019) © Neoleukin Therapeutics. All Rights Reserved.

IL-2 Binds Strongly to Non-Target Cells, Causing Toxicity and Limiting Efficacy



Building a Neoleukin Cytokine Mimetic in 4 Steps





Develop an accurate structural model of the target





Identify regions of intermolecular contact Design an idealized topology

Assign optimal amino acid sequence













Crystal Structure Shows Neo-2/15 Binding Beta/Gamma as Predicted



NL-201 Stimulates CD8 Effector T and NK Cells More Selectively Than IL-2




NL-201 is ~330-fold and ~90-fold more selective for CD8+ T and NK cells (vs. Tregs) than IL-2, respectively
 Walkey et. al, AACR Virtual Annual Meeting II, Abstract #4518, June 2020

1) STAT5 phosphorylation in CD8+ T cells, NK cells, and Tregs was measured by flow cytometry using PBMCs from 10 healthy human donors. Proliferation was evaluated using Ki67.

M neoleukin

NL-201 Stimulates Dose-Dependent CD8:Treg and NK:Treg Proliferation More Potently Than IL-2



Walkey et. al, AACR Virtual Annual Meeting II, Abstract #4518, June 2020


1) NL-201 vs IL-2: * p<0.05; ** p<0.01; *** p<0.001; **** p<0.001

M neoleukin

© Neoleukin Therapeutics. All Rights Reserved.

NL-201: is Well Tolerated and Promotes Durable Antitumor Activity

CT26: syngeneic colon cancer model




- NL-201 is well-tolerated at therapeutic doses
- NL-201 treatment exhibits single-agent activity
 NL-201 promotes durable anti-tumor immunity

1) Study in a checkpoint inhibitor-resistant CT26 colon cancer murine model.

Nr neoleukin

NL-201 Demonstrates Robust Single-Agent Activity in Multiple Tumor Models




NL-201 was administered QWx2 when tumors reached ~100mm3. Tumor growth inhibition (TGI) is reported in each graph vs. control.
 NL-201 treatment inhibited tumor growth in all models: NL-201 significantly inhibited tumor growth in models that are typically refractory to anti-PD-1 checkpoint inhibitors.

Walkey et. al, AACR Virtual Annual Meeting II, Abstract #4518, June 2020

M neoleukin

© Neoleukin Therapeutics. All Rights Reserved.

NL-201 Shows Minimal Immunogenicity in NHPs




- ADAs were detectable in: 3/10 NHPs at 5µg/kg; 1/6 NHPs at 15µg/kg; 0/10 NHPs at 50µg/kg NL-201
- 3 of 4 ADA+ NHPs were at or below the low positive control (LPC) level



Abstract #4518, Walkey et. al, AACR Virtual Annual Meeting II, June 2020

14

Similar Pharmacodynamics and Tolerability Observed in ADA+ vs ADA- NHPs




Adapted from Abstract #4518, Walkey et. al, AACR Virtual Annual Meeting II, June 2020



© Neoleukin Therapeutics. All Rights Reserved.

NL-201 Phase 1 Clinical Trial in Solid Tumors

- IV, monotherapy in patients with relapsed or refractory solid tumors
- Part 1: Identify optimal dose and schedule; assess safety, PK, PD, and antitumor activity
- Part 2: Indication-specific expansion cohorts, including renal cell carcinoma and melanoma
- Clinical sites in Australia, U.S. and Canada
- Enrollment up to 120 patients
- Interim data expected in 2022





© Neoleukin Therapeutics. All Rights Reserved

Naing et al, SITC Nov 2021

NL-201: Broad Clinical Opportunity

- Plan to initiate a trial for patients with heme malignancies in 2022
 - IL-2 and IL-15 have activity in multiple B-cell lineage preclinical models
 - Abstract to be presented at ASH 2021 (Atlanta, GA) on antitumor activity of NL-201 in multiple myeloma
- Future opportunities to combine with checkpoint inhibitors, monoclonal antibodies, cellular therapies, and other standard-of-care agents
- Potential advantages of NL-201 local administration presented at SITC 2021



NL-201 Turns 'Cold' Tumor 'Hot' Augments inflammatory milieu in preclinical B16 melanoma model

CD8+GrB+T cells

00

Vehicle

 \triangle

NL-201

anti-PD-1

NL-201

+ anti-PD-1

(co-admin)

1600

1200

800

400

0

cell counts (cells/mg of tumor)

TCRβ Sequencing Summary				
Mean (range)	Total T cells	Unique T cells	Simpson Clonality	
Vehicle (n=5)	1,406 (358-2,708)	445 (196-807)	0.194 (0.106-0.411)	
anti-PD-1 (n=5)	2,456 (987-4,713)	464 (314-775)	0.34 (0.138-0.57)	
NL-201 (n=5)	2,664 (1,578-3,816)	869 (611-1,064)	0.206 (0.11-0.292)	
NL-201 plus anti-PD-1 (co-admin) (n=5)	2,865 (1,504-3,456)	1,042 (536-1,486)	0.128 (0.073-0.165)	

CD4⁺IFNy⁺Th1 cells

0

8

°08 8


ns

毘

20



- increases T-cell diversity in the tumor microenvironment
- augments IFNγ and granzyme B expression in T-cells
- synergizes with anti-PD1 to inhibit tumor growth



Mortales et. Al, SITC 2021, Abstract #716, Nov 2021

cell counts (cells/mg of tumor)

600 -400 -200 -150 -

100

50

0

M neoleukin

CD8⁺IFNy⁺T cells

8 00

2000

1500

1000


500

n

cell counts (cells/mg of tumor)

© Neoleukin Therapeutics. All Rights Reserved.

NL-201 Upregulates PD-1 Expression by CD8+ T Cells




- NL-201 induces concentrationdependent PD-1 expression by CD8+ T cells
- Combining NL-201 with a checkpoint inhibitor may overcome PD-L1 mediated T cell inhibition

Walkey et. Al, SITC 2020, Abstract #576, November 2020




NL-201 Enhances Activity of Checkpoint Inhibitors in Preclinical Models

- NL-201 enhances activity of CPIs in breast and kidney cancer models
- Combination with NL-201 beneficial in CPI-resistant syngeneic tumors



NL-201: 90μg/kg QWx2 αPD-1: 10mg/kg BiWx6 αCTLA-4: 10gm/kg BiWx6 Treatment began when tumors reached ~90mm³

Promising NL-201 Preclinical Combinations In Vivo Enhanced antitumor activity with CAR-T cells and antibodies




Leung et. al, AACR Annual Meeting II, Abstract #2222, June 2020

M neoleukin


© Neoleukin Therapeutics. All Rights Reserved.

B16 Melanoma Model




Walkey et. Al, SITC 2020, Abstract #576, November 2020

Intratumoral NL-201: Local and Distant Antitumor Activity with Improved Tolerability




© Neoleukin Therapeutics. All Rights Reserved.

Neoleukin Cytokine Mimetics are Hyperstable and Easily Modified



© Neoleukin Therapeutics. All Rights Reserved.

Neo-5171: A computationally designed de novo protein inhibitor of IL-2 and IL-15 signaling




M neoleukin

R. Swanson et. al. Am. Coll Rheum. (ACR) 2021; Abstract 1438, Nov 2021

© Neoleukin Therapeutics. All Rights Reserved.


Neo-5171-Fc prolongs survival in a preclinical model of graft-vs-host disease (GVHD)



R. Swanson et. al. Amer Coll Rheum (ACR) 2021; Abstract 1438, Nov 2021



De Novo Split Technology - Conditionally Active IL-2 Mimetic




Quijano-Rubio et. Al., AACR Virtual Annual Meeting II, Abstract #1075, Jun/2020



© Neoleukin Therapeutics. All Rights Reserved.

Targeted Split Neo-2/15 Increases Therapeutic Window



Notes:

Days after tumor inoculation

- 1) C57BL/6J mice bearing B16 PDL1Hi melanoma cells in flank.
- 2) All groups were co-treated biweekly with Ta99 mAb (150µg/mice)
- 3) Targeted Neo-2/15 variants and Part-A fusions administered i.p.; Part-B fusions
- administered s.c. opposite flank of tumor

Quijano-Rubio et. Al., AACR Virtual Annual Meeting II, Abstract #1075, Jun/2020



Functional De Novo Proteins

Better Therapies by Design

nature

2019

Article | Published: 09 January 2019

De novo design of potent and selective mimics of IL-2 and IL-15

Daniel-Adriano Silva 🖂, Shawn Yu, Umut Y. Ulge, Jamie B. Spangler, Kevin M. Jude, Carlos Labão-Almeida, Lestat R. Ali, Alfredo Quijano-Rubio, Mikel Ruterbusch, Isabel Leung, Tamara Biary, Stephanie J. Crowley, Enrique Marcos, Carl D. Walkey, Brian D. Weitzner, Fátima Pardo-Avila, Javier Castellanos, Lauren Carter, Lance Stewart, Stanley R. Riddell, Marion Pepper, Gonçalo J. L. Bernardes, Michael Dougan, K. Christopher Garcia 🗠 & David Baker 🖂

Science

2020

CORONAVIRUS Article | Published: 4 December 2020


De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Thomas W. Linsky¹⁴, Renan Vergara¹⁴, Nuria Codina¹⁵, Jorgen W. Nelson¹⁴, Matthew J. Walker¹, Wen Su², Christopher O. Barnes³, Tien-Ying Hsiang⁴, Katharina Esser-Nobis⁴, Kevin Yu¹, Z. Beau Reneer⁵, Yixuan J. Hou⁴, Tanu Priya¹, Masaya Mitsumoto¹, Avery Pong¹, Uland Y. Lau¹, Marsha L. Mason¹, Jerry Chen¹, Alex Chen¹, Tania Berrocal¹, Hong Peng¹, Nicole S. Clairmont¹, Javier Castellanos¹, Yu-Ru Lin¹, Anna Josephson-Day¹, Ralph S. Barle⁶, Deborah H. Fuller⁷, Carl D. Walkey¹, Ted M. Ross^{5,8}, Ryan Swanson¹, Pamela J. Bjorkman³, Michael Gale Jr.⁴, Luis M. Blancas-Mejia¹, Hui-Ling Yen², Daniel-Adriano Silva¹[†]

- · Scientific founders are world leaders in de novo protein design
- · Technology originated at University of Washington Institute for Protein Design
- · Exclusive license obtained for commercialization of NL-201 and other de novo protein assets


De Novo Platform Potential – COVID-19


SARS-CoV-2 uses ACE2 as a receptor to gain access to and infect cells



NL-CVX1 - de novo ACE2 decoy:


- Binds to SARS-CoV2 spike protein
- Inhibits viral infection in vitro
- Designed, tested, optimized in ~10 weeks





NL-CVX1 – *De Novo* Protein Decoy

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2



T. W. Linsky et. al. Science. 10.1126/science.abe0075 (2020)



Financial Highlights & Upcoming Milestones

Financial

- \$154.9 million cash & cash equivalents as of September 30, 2021
- Cash and cash equivalents expected to fund operations into 2H 2023
- 42.4M common shares outstanding and 12.7M pre-funded warrants¹

Upcoming Milestones

- Expect to release NL-201 interim phase 1 data in 2022
- Plan to initiate phase 1 heme malignancy trial for NL-201

¹ Warrants to purchase common shares 1:1 with an exercise price of \$0.000001 as of September 30, 2021.





Improving on nature. Designing for life.